Get the Stockscreener App
2.04
7.27%
-0.16
After Hours:
2.03
-0.01
-0.49%
Genprex Inc stock is traded at $2.04, with a volume of 283.86K.
It is down -7.27% in the last 24 hours and down -21.54% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
See More
Previous Close:
$2.20
Open:
$2.15
24h Volume:
283.86K
Relative Volume:
0.42
Market Cap:
$4.63M
Revenue:
-
Net Income/Loss:
$-22.71M
P/E Ratio:
-0.1742
EPS:
-11.71
Net Cash Flow:
$-18.24M
1W Performance:
+4.08%
1M Performance:
-21.54%
6M Performance:
-82.60%
1Y Performance:
-91.42%
1-Day Range:
$1.99
$2.15
1-Week Range:
$1.99
$2.29
52-Week Range:
$1.71
$55.00
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
2.04 | 4.99M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
Genprex receives patent approval in Australia for cancer therapy By Investing.com - Investing.com Canada
Genprex (GNPX) Gains Australian Patent Approval for Cancer Treat - GuruFocus
Genprex Gains Australian Patent Acceptance for REQORSA Therapy - TipRanks
Genprex Announces Ip Australia's Intent To Grant Patent For Reqorsa® Gene Therapy - TradingView
Genprex Patent Acceptance and Clinical Trial Expansion - TradingView
Genprex (NASDAQ: GNPX) advances REQORSA patent strategy and expands Acclaim-3 lung cancer trial - Stock Titan
Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers - PR Newswire
Bull Run: Will Genprex Inc benefit from green energy policiesPortfolio Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Genprex Shares Seek Catalysts Amid Clinical Trial Focus - AD HOC NEWS
Institution Moves: What are the analyst revisions for Guess IncIs Genprex Inc stock a good investment in YEARExit Point & Short-Term Trading Alerts - baoquankhu1.vn
Aug PreEarnings: Will Genprex Inc outperform tech stocksShort Setup & Safe Entry Point Identification - baoquankhu1.vn
Aug Patterns: Whats the outlook for TMD Energy Limiteds sectorWeekly Trade Summary & Weekly Chart Analysis and Guides - baoquankhu1.vn
Genprex, Inc. Stock (GNPX) Opinions on GPX-002 Diabetes Therapy Data - Quiver Quantitative
Aug Spikes: How does Genprex Inc score in quality rankingsFed Meeting & High Accuracy Investment Signals - baoquankhu1.vn
Take Profit: Is Genprex Inc stock a defensive play in 20252025 Sector Review & Verified Stock Trade Ideas - Bộ Nội Vụ
Genprex Regains Nasdaq Compliance but Faces Ongoing Monitoring - The Globe and Mail
MSN Money - MSN
Genprex Regains Nasdaq Compliance - TradingView — Track All Markets
Congressman who was top 2025 stock picker buys shares of $5M company you've never heard of - MSN
Congressman Who Was Top 2025 Stock Picker Buys Shares Of $5M Company You've Never Heard Of - Benzinga
Rep. Tim Moore Purchases Shares of Genprex (NASDAQ:GNPX) - Defense World
Will Genprex Inc. stock remain a Wall Street favorite2025 Technical Patterns & Daily Oversold Stock Bounce Ideas - ulpravda.ru
Can Genprex Inc. stock beat market expectations this quarterShort Setup & Safe Entry Point Identification - ulpravda.ru
Can Genprex Inc. stock sustain market leadershipWeekly Trading Summary & AI Based Trade Execution Alerts - Улправда
PRN_FinancialWrapper | PR NewswireGenprex, Inc.Common Stock (Nasdaq:GNPX) Price Chart - FinancialContent
Why analysts upgrade Genprex Inc. stock2025 Market WrapUp & Risk Controlled Swing Alerts - ulpravda.ru
How Genprex Inc. stock reacts to inflationary pressuresJuly 2025 PreEarnings & Entry and Exit Point Strategies - Улправда
Is Genprex Inc. stock a bargain at current levelsSwing Trading Watchlist & Optimize Entry & Exit With Smart Signals - Улправда
Genprex Advances Diabetes Gene Therapy Program With Preclinical Milestones - Nasdaq
Genprex reports in vivo proof of concept for GPX-002 - BioWorld MedTech
Genprex reports positive data for diabetes gene therapy in animal studies - Investing.com Nigeria
Genprex advances GPX-002 diabetes gene therapy program - TipRanks
Genprex, Inc. Announces Updates on Diabetes Gene Therapy Program - TradingView — Track All Markets
Genprex Provides Clinical Update on Diabetes Gene Therapy Program - Barchart.com
Genprex Advances Diabetes Gene Therapy with Key Milestones Achieved in 2025 - Intellectia AI
What catalysts could drive Genprex Inc. stock higher2026 world cup usa national team semifinals young talents build up play odds analysis expert opinion - ulpravda.ru
Genprex reports positive preclinical results for GPX-002 diabetes therapy - MSN
Genprex Inc surges 9.44% amid market context - Intellectia AI
Genprex Reports Positive Preclinical Data for Diabetes Gene Therapy in Animal Studies; Shares Rise - marketscreener.com
Genprex Reports Positive Preclinical Data For Diabetes Gene Therapy Candidate GPX-002 - Nasdaq
Genprex Announces Positive Preliminary Preclinical Data from Stu - GuruFocus
Genprex reports positive data for diabetes gene therapy in animal studies By Investing.com - Investing.com South Africa
Genprex Reports Positive Preclinical Results for GPX-002 Diabetes Therapy - TipRanks
Genprex Announces Positive Preclinical Data for GPX-002 in Diabetes - TradingView — Track All Markets
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies - PR Newswire
Genprex (GNPX) Stock Analysis Report | Financials & Insights - Benzinga Italia
Published on: 2025-12-29 06:37:03 - moha.gov.vn
Genprex reports potential compliance with Nasdaq equity listing rule By Investing.com - Investing.com Canada
Genprex (GNPX) awards 28,500 RSUs to Chief Medical Officer under 2018 plan - Stock Titan
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):